Both signatures demonstrated a satisfactory predictive accuracy for response: AUC of 0.69 (95% CI: 0.54, 0.84) for the inflammatory and 0.70 (95% CI: 0.55, 0.85) for EMT signatures, respectively.... 36 (69%) patients were treated with nivolumab, 14 (27%) with pembroluzimab, and 2 (4%) with atezoluzimab....Because both the inflammatory and EMT gene signatures were significantly associated with response rates, we evaluated their relationship and noted a positive correlation between the two signatures (r2 = 0.32, p < 0.0001).